Leber's hereditary optic neuropathy

(redirected from Leber optic atrophy)

Leber's hereditary optic neuropathy

A rare genetic disease inherited from the mother caused by a point mutation in MITOCHONDRIAL DNA. Onset is usually about the 20th year and males are affected more often than females. It features changes in the small retinal blood vessels progressing to a degree of atrophy of the optic nerves in both eyes with a severe defect in visual acuity. In most cases a visual acuity of about 6/60-one tenth of normal-is retained. (T. von Leber, 1040–1917, German ophthalmologist and professor of ophthalmology at Heidelberg).
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
Global Markets Direct's, 'Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H1 2016', provides an overview of the Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
* The report reviews pipeline therapeutics for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) by companies and universities/research institutes based on information derived from company and industry-specific sources
Global Markets Direct's, 'Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2015', provides an overview of the Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)'s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
* A review of the Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Full browser ?